Zobrazeno 1 - 10
of 146
pro vyhledávání: '"Hesterlee S"'
Autor:
Kilroy EA; Muscular Dystrophy Association, Chicago, IL, USA., Burris R; Muscular Dystrophy Association, Chicago, IL, USA., Javelosa E; Muscular Dystrophy Association, Chicago, IL, USA., Waits J; Muscular Dystrophy Association, Chicago, IL, USA., Lek A; Muscular Dystrophy Association, Chicago, IL, USA., Rodgers R; Kinevant Sciences, New York, NY, USA., Opgenorth H; Axogen, Alachua, FL, USA., Hesterlee S; Muscular Dystrophy Association, Chicago, IL, USA.
Publikováno v:
Journal of neuromuscular diseases [J Neuromuscul Dis] 2023; Vol. 10 (3), pp. 365-380.
Publikováno v:
In Neuromuscular Disorders October 2022 32 Supplement 1:S57-S57
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Levitan B; Janssen R&D, Titusville, NJ, USA., Getz K; Tufts Center for the Study of Drug Development, Boston, MA, USA., Eisenstein EL; Duke University, Durham, NC, USA., Goldberg M; Johnson and Johnson, Titusville, NJ, USA., Harker M; Duke-Margolis Center for Health Policy, Durham, NC, USA., Hesterlee S; Bamboo Therapeutics, Durham, NC, USA., Patrick-Lake B; Clinical Trials Transformation Initiative, Durham, NC, USA., Roberts JN; Clinical Trials Transformation Initiative, Durham, NC, USA. jamie.roberts@dm.duke.edu.; Duke Clinical and Translational Science Institute, Durham, NC, USA. jamie.roberts@dm.duke.edu., DiMasi J; Tufts Center for the Study of Drug Development, Boston, MA, USA.
Publikováno v:
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2018 Mar; Vol. 52 (2), pp. 220-229. Date of Electronic Publication: 2017 Jul 17.
Autor:
Bloom D; Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA., Beetsch J; Celgene Corporation, Summit, NJ, USA., Harker M; Duke-Margolis Center for Health Policy, Durham, NC, USA., Hesterlee S; Parent Project Muscular Dystrophy, Hackensack, NJ, USA., Moreira P; EMD Serono, Rockland, MA, USA., Patrick-Lake B; Clinical Trials Transformation Initiative, Durham, NC, USA., Selig W; WSCollaborative, McLean, VA, USA., Sherman J; Drug Information Association/Horizon Pharma, Lake Forest, IL, USA., Smith SK; Duke University School of Nursing, Durham, NC, USA., Valentine JE; Hyman, Phelps & McNamara, PC, Washington, DC, USA., Roberts JN; Clinical Trials Transformation Initiative, Durham, NC, USA. jamie.roberts@dm.duke.edu.; Duke Clinical and Translational Science Institute, Durham, NC, 27710, USA. jamie.roberts@dm.duke.edu.
Publikováno v:
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2018 Mar; Vol. 52 (2), pp. 206-213. Date of Electronic Publication: 2017 Jul 27.
Autor:
Hesterlee S; 1 Myotonic Dystrophy Foundation, San Francisco, CA, USA., Amur S; 2 Office of Translational Sciences, CDER, FDA, Silver Spring, MD, USA., Bain LJ; 3 Science Writer, Elverson, PA, USA., Carulli J; 4 Precision Medicine, Biogen, Cambridge, MA, USA., Clarke S; 5 Patient and caregiver, NY, USA., Day JW; 6 Department of Neurology, School of Medicine, Stanford University, Palo Alto, CA, USA., Gagnon C; 7 School of Rehabilitation, Université de Sherbrooke, Quebec, Canada., Hagerman K; 6 Department of Neurology, School of Medicine, Stanford University, Palo Alto, CA, USA., Heatwole C; 8 Department of Neurology, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA., Johnson NE; 9 Department of Neurology, School of Medicine, University of Utah, Salt Lake City, UT, USA., Moxley R 3rd; 8 Department of Neurology, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA., Patel N; 10 Office of New Drugs, CDER, FDA, Silver Spring, MD, USA., Thornton C; 8 Department of Neurology, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA., Kessel W; 1 Myotonic Dystrophy Foundation, San Francisco, CA, USA., White M; 1 Myotonic Dystrophy Foundation, San Francisco, CA, USA.
Publikováno v:
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2017 Jul; Vol. 51 (4), pp. 516-522. Date of Electronic Publication: 2017 Feb 09.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Saraff, Vrinda1,2 (AUTHOR) vrinda.saraff@nhs.net, Boot, Annemieke M.3 (AUTHOR), Linglart, Agnès4 (AUTHOR), Semler, Oliver5 (AUTHOR), Harvengt, Pol6 (AUTHOR), Williams, Angela7 (AUTHOR), Bailey, Karen M. A.8 (AUTHOR), Glen, Fiona8 (AUTHOR), Davies, Elin Haf9 (AUTHOR), Wood, Sue7 (AUTHOR), Greentree, Stephen7 (AUTHOR), Rylands, Angela J.7 (AUTHOR)
Publikováno v:
PLoS ONE. 1/19/2024, Vol. 19 Issue 1, p1-15. 15p.
Autor:
Smith SK; School of Nursing, Duke University, Durham, NC, United States of America., Selig W; WS Collaborative, McLean, VA, United States of America., Harker M; Clinical Trials Transformation Initiative, Duke Clinical Research Institute, Durham, NC, United States of America., Roberts JN; Clinical Trials Transformation Initiative, Duke Clinical Research Institute, Durham, NC, United States of America., Hesterlee S; Parent Project Muscular Dystrophy, Hackensack, NJ, United States of America., Leventhal D; Pfizer Worldwide Research and Development, Groton, CT, United States of America., Klein R; U.S. Food and Drug Administration, Silver Spring, MD, United States of America., Patrick-Lake B; Clinical Trials Transformation Initiative, Duke Clinical Research Institute, Durham, NC, United States of America., Abernethy AP; Flatiron Health, New York, NY, United States of America.
Publikováno v:
PloS one [PLoS One] 2015 Oct 14; Vol. 10 (10), pp. e0140232. Date of Electronic Publication: 2015 Oct 14 (Print Publication: 2015).